CO6231028A2 - Compuestos y composiciones como inhibidores de la proteina quinasa - Google Patents
Compuestos y composiciones como inhibidores de la proteina quinasaInfo
- Publication number
- CO6231028A2 CO6231028A2 CO09070739A CO09070739A CO6231028A2 CO 6231028 A2 CO6231028 A2 CO 6231028A2 CO 09070739 A CO09070739 A CO 09070739A CO 09070739 A CO09070739 A CO 09070739A CO 6231028 A2 CO6231028 A2 CO 6231028A2
- Authority
- CO
- Colombia
- Prior art keywords
- independently
- alkyl
- optionally substituted
- alkynyl
- alkenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La invención proporciona nuevos derivados de pirimidina y piridina y composiciones farmacéuticas y métodos para el uso de dichos compuestos. Por ejemplo, derivados de pirimidina y piridina de la invención pueden ser utilizados para tratar, aliviar o prevenir a una condición que responda a la inhibición de la actividad de la quinasa del linfoma anaplásico (ALK), la quinasa de adhesión focal (FAK), la proteína quinasa 70 asociada a la cadena zeta (ZAP-70), el factor de crecimiento tipo insulina (IGF-1R), o una combinación de éstos. 1.- Un compuesto que tiene la Fórmula (I):o sales farmacéuticamente aceptables del mismo; dondeW es A1 y A4 son independientemente C o N; cada A2 yA3 es C, o uno de A2 y A3 es N donde R6 y R7 forman un anillo; B y C son independientemente un anillo carbocíclico de 5-7 miembros opcionalmente sustituido, aril, heteroaril o un anillo heterocíclico que contiene N, O o S; Z1, Z2 y Z3 son independientemente NR11, C=O, CR-OR, (CR2)1-2 o =C-R12; R1 y R2 son independientemente halo, OR12, NR(R12), SR12, o un C1-6alquil, C2-6 alquenil o C2-6 alquinil, opcionalmente sustituidos; o uno de R1 y R2 es H; R3 es (CR2)0-2SO2R12, (CR2)0-2SO2NRR12, (CR2)0-2CO1-2R12, (CR2)0-2CONRR12 o ciano; R4, R6, R7 y R10 son independientemente un C1-6 alquil, C2-6 alquenil o C2-6 alquinil, opcionalmente sustituidos; OR12, NR(R12), halo, nitro, SO2R12, (CR2)pR13 o X; o R4, R7 y R10 son independientemente H; R, R5 y R5´ son independientemente H o C1-6 alquil; R8 y R9 son independientemente C1-6 alquil, C2-6 alquenil, C2-6 alquinil, halo o X, o uno de R8 y R9 es H donde R1 y R2 forman un anillo; y siempre que uno de R8 y R9 es X;alternativamente, R1 y R2, o R6 y R7, R7 y R8, o R9 y R10, cuyo están unidos a un átomo de carbono puede formar un anillo carbocíclico monocíclico o fusionado de 5-7 miembros opcionalmente sustituido, aril, o ...
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86929906P | 2006-12-08 | 2006-12-08 | |
US96644907P | 2007-08-28 | 2007-08-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6231028A2 true CO6231028A2 (es) | 2010-12-20 |
Family
ID=39370882
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09070739A CO6231028A2 (es) | 2006-12-08 | 2009-07-08 | Compuestos y composiciones como inhibidores de la proteina quinasa |
Country Status (30)
Country | Link |
---|---|
EP (1) | EP2091918B1 (es) |
JP (3) | JP5208123B2 (es) |
KR (1) | KR101149295B1 (es) |
CN (2) | CN103641833A (es) |
AU (3) | AU2007333394C1 (es) |
BR (1) | BRPI0720264B1 (es) |
CA (1) | CA2671744C (es) |
CO (1) | CO6231028A2 (es) |
CR (1) | CR10832A (es) |
CY (1) | CY2015043I1 (es) |
DK (1) | DK2091918T3 (es) |
EA (1) | EA017405B9 (es) |
EC (1) | ECSP099500A (es) |
FR (1) | FR15C0058I2 (es) |
GT (1) | GT200900147A (es) |
HU (1) | HUS1500049I1 (es) |
IL (1) | IL198936A0 (es) |
LT (1) | LTC2091918I2 (es) |
MA (1) | MA30923B1 (es) |
ME (1) | ME00811B (es) |
MX (1) | MX2009006081A (es) |
NL (1) | NL300763I1 (es) |
NO (3) | NO338069B1 (es) |
PL (1) | PL2091918T3 (es) |
PT (1) | PT2091918E (es) |
SM (1) | SMP200900058B (es) |
SV (1) | SV2009003290A (es) |
TN (1) | TN2009000225A1 (es) |
WO (1) | WO2008073687A2 (es) |
ZA (1) | ZA200903601B (es) |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008045663A2 (en) * | 2006-10-06 | 2008-04-17 | Kalypsys, Inc. | Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents |
EP2684874B1 (en) | 2006-10-23 | 2017-05-17 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors |
CA2671744C (en) * | 2006-12-08 | 2012-08-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
AU2007337088A1 (en) * | 2006-12-19 | 2008-07-03 | Genentech, Inc. | Pyrimidine kinase inhibitors |
CL2008000197A1 (es) | 2007-01-26 | 2008-08-01 | Smithkline Beecham Corp | Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. |
CN101679264A (zh) | 2007-03-16 | 2010-03-24 | 斯克里普斯研究学院 | 粘着斑激酶抑制剂 |
TWI389893B (zh) * | 2007-07-06 | 2013-03-21 | Astellas Pharma Inc | 二(芳胺基)芳基化合物 |
AU2008296479A1 (en) * | 2007-08-28 | 2009-03-12 | Dana Farber Cancer Institute | Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis |
BRPI0815979A2 (pt) * | 2007-08-28 | 2017-06-13 | Irm Llc | compostos e composições com inibidores de quinase, bem como uso dos mesmos |
CN101868459B (zh) | 2007-09-21 | 2013-12-18 | 阿雷生物药品公司 | 用于治疗糖尿病的、作为葡糖激酶激活剂的吡啶-2-基-氨基-1,2,4-噻二唑衍生物 |
WO2009105498A1 (en) * | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
EP2271630B1 (en) * | 2008-04-07 | 2016-03-23 | Novartis AG | Compounds and compositions as protein kinase inhibitors |
WO2009127642A2 (en) * | 2008-04-15 | 2009-10-22 | Cellzome Limited | Use of lrrk2 inhibitors for neurodegenerative diseases |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
MX353308B (es) | 2008-05-21 | 2018-01-08 | Ariad Pharma Inc | Derivados fosforosos como inhibidores de cinasa. |
EP2303861B1 (en) | 2008-06-17 | 2014-04-23 | AstraZeneca AB | Pyridine compounds |
US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
JP2011526291A (ja) * | 2008-06-25 | 2011-10-06 | アイアールエム・リミテッド・ライアビリティ・カンパニー | キナーゼ阻害剤としてのピリミジン誘導体 |
UY31929A (es) * | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
KR20110025224A (ko) | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | 헤테로아릴 화합물 및 이의 용도 |
KR20110058864A (ko) * | 2008-09-03 | 2011-06-01 | 바이엘 크롭사이언스 아게 | 살진균제로서의 헤테로사이클 치환된 아닐리노피리미딘 |
TW201100427A (en) | 2009-03-31 | 2011-01-01 | Arqule Inc | Substituted heterocyclic compounds |
CN102482277B (zh) * | 2009-05-05 | 2017-09-19 | 达纳-法伯癌症研究所有限公司 | 表皮生长因子受体抑制剂及治疗障碍的方法 |
LT3009428T (lt) | 2009-05-08 | 2018-04-10 | Astellas Pharma Inc. | Diamino heterociklinis karboksamido junginys |
WO2010138578A1 (en) * | 2009-05-27 | 2010-12-02 | Abbott Laboratories | Pyrimidine inhibitors of kinase activity |
ES2608670T3 (es) | 2009-08-17 | 2017-04-12 | Memorial Sloan-Kettering Cancer Center | Derivados de 2-(pirimidin-5-il)-tiopirimidina como moduladores de Hsp70 y Hsc70 para el tratamiento de trastornos proliferativos |
NZ598705A (en) | 2009-09-16 | 2014-06-27 | Celgene Avilomics Res Inc | Protein kinase conjugates and inhibitors |
EP2512246B1 (en) | 2009-12-17 | 2015-09-30 | Merck Sharp & Dohme Corp. | Aminopyrimidines as syk inhibitors |
CA2782889C (en) | 2009-12-17 | 2014-08-05 | Merck Canada Inc. | Aminopyrimidines as syk inhibitors |
SG181965A1 (en) | 2009-12-30 | 2012-08-30 | Avila Therapeutics Inc | Ligand-directed covalent modification of protein |
EP2544672A1 (en) | 2010-03-09 | 2013-01-16 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
CN103038230B (zh) | 2010-06-04 | 2016-05-25 | 霍夫曼-拉罗奇有限公司 | 作为lrrk2调节剂的氨基嘧啶衍生物 |
SG187796A1 (en) | 2010-08-10 | 2013-03-28 | Celgene Avilomics Res Inc | Besylate salt of a btk inhibitor |
NZ609957A (en) | 2010-11-01 | 2015-08-28 | Celgene Avilomics Res Inc | Heterocyclic compounds and uses thereof |
EP2635285B1 (en) | 2010-11-01 | 2017-05-03 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
NO2638031T3 (es) | 2010-11-10 | 2018-03-10 | ||
EP3453708B8 (en) * | 2010-12-17 | 2022-03-16 | Novartis AG | Process for the preparation of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine di-hydrochloride |
WO2012097479A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Bicyclic inhibitors of anaphastic lymphoma kinase |
DK2670401T3 (en) * | 2011-02-02 | 2015-09-07 | Novartis Ag | Methods for using the ALK-inhibitors |
GB201104267D0 (en) * | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
CA2832504C (en) | 2011-05-04 | 2019-10-01 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
EP2707357B1 (en) | 2011-05-10 | 2017-01-18 | Merck Sharp & Dohme Corp. | Pyridyl aminopyridines as syk inhibitors |
BR112013028900A2 (pt) | 2011-05-10 | 2017-01-03 | Merck Sharp & Dohe Corp | Composto, composição farmacêutica, e, método para o tratamento ou a prevenção de doenças |
WO2012154518A1 (en) | 2011-05-10 | 2012-11-15 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as syk inhibitors |
TW201325593A (zh) | 2011-10-28 | 2013-07-01 | Celgene Avilomics Res Inc | 治療布魯頓(bruton’s)酪胺酸激酶疾病或病症之方法 |
CN104203924B (zh) | 2012-01-13 | 2019-06-11 | 艾森生物科学公司 | 杂环化合物及其作为抗癌药的用途 |
US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
MX356179B (es) | 2012-03-15 | 2018-05-17 | Celgene Avilomics Res Inc | Sales de un inhibidor de cinasa del receptor del factor de crecimiento epidermico. |
MX356753B (es) | 2012-03-15 | 2018-06-12 | Celgene Avilomics Res Inc | Formas solidas de un inhibidor de cinasa del receptor del factor de crecimiento epidermico. |
FR2988722B1 (fr) | 2012-04-03 | 2014-05-09 | Sanofi Sa | Nouveaux derives de thienopyrimidines, leurs procedes de preparation et leurs utilisations therapeutiques |
JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
CA2890006C (en) | 2012-11-06 | 2021-11-23 | Shanghai Fochon Pharmaceutical Co Ltd | Alk kinase inhibitors |
CN105120868A (zh) * | 2012-11-07 | 2015-12-02 | 诺华股份有限公司 | 组合治疗 |
WO2014100748A1 (en) | 2012-12-21 | 2014-06-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
US9145387B2 (en) | 2013-02-08 | 2015-09-29 | Celgene Avilomics Research, Inc. | ERK inhibitors and uses thereof |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
CN104109149B (zh) | 2013-04-22 | 2018-09-28 | 苏州泽璟生物制药有限公司 | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 |
KR20160020502A (ko) * | 2013-06-18 | 2016-02-23 | 노파르티스 아게 | 제약 조합물 |
CN117486865A (zh) | 2013-07-11 | 2024-02-02 | 艾森医药公司 | 嘧啶衍生物作为激酶抑制剂 |
RU2656591C2 (ru) * | 2013-07-11 | 2018-06-06 | Бетта Фармасьютикалз Ко., Лтд | Модуляторы протеин-тирозинкиназы и способы их применения |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
EP3038652B1 (en) * | 2013-08-28 | 2018-03-21 | Novartis AG | Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases |
US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
BR112016012506A8 (pt) * | 2013-12-23 | 2018-01-30 | Novartis Ag | combinações farmacêuticas, seus usos, e uso de um portador de dados |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
AU2015229103C9 (en) | 2014-03-14 | 2020-11-26 | Immutep S.A.S | Antibody molecules to LAG-3 and uses thereof |
SG11201609336PA (en) | 2014-05-13 | 2016-12-29 | Sloan Kettering Inst Cancer | Hsp70 modulators and methods for making and using the same |
SG11201609208UA (en) * | 2014-05-29 | 2016-12-29 | Novartis Ag | Ceritinib formulation |
CN105272921A (zh) * | 2014-06-09 | 2016-01-27 | 江苏奥赛康药业股份有限公司 | 一种制备Ceritinib的方法及其中间体化合物 |
CN103992262B (zh) * | 2014-06-12 | 2015-11-11 | 苏州明锐医药科技有限公司 | 塞瑞替尼及其中间体的制备方法 |
CN106459007B (zh) * | 2014-06-17 | 2020-02-28 | 韩国化学研究院 | 嘧啶-2,4-二胺衍生物及包含其作为有效成分的抗癌用药学组合物 |
ES2741785T3 (es) | 2014-08-13 | 2020-02-12 | Celgene Car Llc | Formas y composiciones de un inhibidor de ERK |
US11344620B2 (en) | 2014-09-13 | 2022-05-31 | Novartis Ag | Combination therapies |
KR101909404B1 (ko) | 2014-09-29 | 2018-10-17 | 수안주 파마 코포레이션 리미티드 | 역형성 림프종 키나제의 폴리사이클릭 저해제 |
CN107106687A (zh) | 2014-10-03 | 2017-08-29 | 诺华股份有限公司 | 组合治疗 |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
MA40035A (fr) | 2014-10-14 | 2016-04-21 | Dana Farber Cancer Inst Inc | Molécules d'anticorps de pd-l1 et leurs utilisations |
US20170252335A1 (en) | 2014-10-17 | 2017-09-07 | Novartis Ag | Combination of Ceritinib with an EGFR Inhibitor |
EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
WO2016098070A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine |
WO2016098042A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders |
CN105777617B (zh) * | 2014-12-26 | 2018-11-06 | 上海医药工业研究院 | 色瑞替尼的合成中间体及其制备方法 |
CN105777616B (zh) * | 2014-12-26 | 2018-12-07 | 上海医药工业研究院 | 色瑞替尼的合成中间体及其制备方法 |
US9296721B1 (en) * | 2015-02-13 | 2016-03-29 | Yong Xu | Method for preparing ALK inhibitor ceritinib |
EP3256475A4 (en) | 2015-02-13 | 2019-02-13 | Dana-Farber Cancer Institute, Inc. | LRRK2 INHIBITORS AND METHOD FOR THE PRODUCTION AND USE THEREOF |
AU2015385326B2 (en) * | 2015-03-04 | 2019-04-18 | Novartis Ag | Chemical process for preparing pyrimidine derivatives and intermediates thereof |
US10449211B2 (en) | 2015-03-10 | 2019-10-22 | Aduro Biotech, Inc. | Compositions and methods for activating “stimulator of interferon gene”—dependent signalling |
CN106146387A (zh) * | 2015-03-30 | 2016-11-23 | 湖北生物医药产业技术研究院有限公司 | Alk抑制剂的制备方法 |
KR101772134B1 (ko) | 2015-04-14 | 2017-08-29 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
WO2016167511A2 (ko) * | 2015-04-14 | 2016-10-20 | 한국화학연구원 | N2-(2-메톡시페닐)피리미딘 유도체, 이의 제조 방법 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
EP3328848A1 (en) | 2015-07-28 | 2018-06-06 | Zentiva, K.S. | Solid forms of ceritinib free base |
EP3964528A1 (en) | 2015-07-29 | 2022-03-09 | Novartis AG | Combination therapies comprising antibody molecules to lag-3 |
EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
CZ2015613A3 (cs) | 2015-09-09 | 2017-03-22 | Zentiva, K.S. | Způsob přípravy Ceritinibu |
DK3353168T3 (da) * | 2015-09-25 | 2023-10-02 | Dizal Jiangsu Pharmaceutical Co Ltd | Forbindelser og fremgangsmåder til at inhibere jak |
MX2018004332A (es) | 2015-10-09 | 2019-01-10 | Acea Therapeutics Inc | Sales farmaceuticas, formas fisicas y composiciones de inhibidores de pirrolopirimidina cinasa, y metodos para fabricar las mismas. |
CN106565593B (zh) * | 2015-10-10 | 2019-03-01 | 常州市勇毅生物药业有限公司 | 一种色瑞替尼中间体的制备方法 |
BR112018008867A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e seus usos |
CN106699743B (zh) | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
CA3005159A1 (en) * | 2015-11-26 | 2017-06-01 | Novartis Ag | Diamino pyridine derivatives |
AU2016369537B2 (en) | 2015-12-17 | 2024-03-14 | Novartis Ag | Antibody molecules to PD-1 and uses thereof |
WO2017153932A1 (en) | 2016-03-10 | 2017-09-14 | Novartis Ag | Strn-alk fusion as a therapeutic target in gastric cancer |
WO2017175111A1 (en) | 2016-04-04 | 2017-10-12 | Novartis Ag | Strn-alk fusion as a therapeutic target in colorectal cancer |
WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
KR101937529B1 (ko) * | 2016-07-26 | 2019-01-14 | 한국화학연구원 | 신규한 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
CA3040286A1 (en) | 2016-10-21 | 2018-04-26 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
CN110730678B (zh) | 2017-01-10 | 2022-07-15 | 诺华股份有限公司 | 包含alk抑制剂和shp2抑制剂的药物组合 |
KR20190107719A (ko) | 2017-02-27 | 2019-09-20 | 노파르티스 아게 | 세리티닙 및 항-pd-1 항체 분자의 조합물에 대한 투여 일정 |
US11498922B2 (en) | 2017-04-07 | 2022-11-15 | ACEA Therapeutics, Inc. | Pharmaceutical composition comprising N-(3-((2-((3-fluoro-4-(4-methylpiperazin-1-yl phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenylacrylamide |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES |
US11179412B2 (en) | 2017-12-04 | 2021-11-23 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating conditions involving elevated inflammatory response |
CN110092759A (zh) * | 2018-01-31 | 2019-08-06 | 陆柯潮 | 作为抗肿瘤药物的5-氯-2,4-嘧啶衍生物 |
UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
CN112638380B (zh) * | 2018-06-29 | 2024-05-24 | 达纳-法伯癌症研究所有限公司 | 小脑蛋白(crbn)配体 |
CN109593065A (zh) * | 2018-12-03 | 2019-04-09 | 重庆医科大学 | 一类hdac/alk双靶点抑制剂及其制备方法与应用 |
WO2020259553A1 (en) * | 2019-06-25 | 2020-12-30 | Ascentage Pharma (Suzhou) Co., Ltd. | Combination of fak inhibitor and btk inhibitor for treating a disease |
AU2020300619A1 (en) | 2019-07-03 | 2022-01-27 | Sumitomo Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
CN112538072B (zh) * | 2019-09-21 | 2024-02-06 | 齐鲁制药有限公司 | 氨基嘧啶类egfr抑制剂 |
GB201915618D0 (en) | 2019-10-28 | 2019-12-11 | Univ Oslo | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
AU2020385527B2 (en) * | 2019-11-21 | 2023-04-13 | Tyk Medicines, Inc. | Compound used as EGFR kinase inhibitor and use thereof |
EP4074697A4 (en) * | 2019-12-03 | 2024-01-03 | Samjin Pharmaceutical Co., Ltd. | NOVEL ADAMANTANE DERIVATIVES AS FOCAL ADHESION KINASE INHIBITORS |
JP2023507319A (ja) * | 2019-12-16 | 2023-02-22 | コリア リサーチ インスティチュート オブ ケミカル テクノロジー | 新規なピリミジン誘導体及びその用途 |
CN115515949A (zh) * | 2020-03-23 | 2022-12-23 | 齐鲁制药有限公司 | 新型氨基嘧啶类egfr抑制剂 |
CN111484484B (zh) * | 2020-04-13 | 2021-11-23 | 沈阳药科大学 | 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用 |
AU2022404890A1 (en) * | 2021-12-09 | 2024-06-06 | Oncobix Co., Ltd. | Novel heterocyclic-substituted pyrimidine derivative exhibiting cancer cell growth inhibitory effect, and pharmaceutical composition containing same |
TW202333667A (zh) * | 2021-12-13 | 2023-09-01 | 大陸商希格生科(深圳)有限公司 | 嘧啶或吡啶類衍生物及其醫藥用途 |
CN115368366A (zh) * | 2022-08-02 | 2022-11-22 | 江苏省中医药研究院 | 嘧啶并吡唑类化合物及其应用 |
CN115448906B (zh) * | 2022-09-26 | 2024-04-02 | 深圳大学 | 一种2-苯胺基嘧啶类衍生物及其制备方法与应用 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2234609C (en) * | 1995-11-01 | 2006-11-28 | Novartis Ag | 2-amino-6-anilino-purine derivatives and processes for their preparation |
ES2274634T3 (es) * | 1998-08-29 | 2007-05-16 | Astrazeneca Ab | Compuestos de pirimidina. |
GB9828511D0 (en) * | 1998-12-24 | 1999-02-17 | Zeneca Ltd | Chemical compounds |
GB9918035D0 (en) * | 1999-07-30 | 1999-09-29 | Novartis Ag | Organic compounds |
MXPA02007957A (es) * | 2000-02-17 | 2002-11-29 | Amgen Inc | Inhibidores de cinasas. |
GB0004887D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
GB0004890D0 (en) * | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
FR2818642B1 (fr) * | 2000-12-26 | 2005-07-15 | Hoechst Marion Roussel Inc | Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion |
CA2441492C (en) * | 2001-03-23 | 2011-08-09 | Bayer Corporation | Rho-kinase inhibitors |
ES2280517T3 (es) * | 2001-03-23 | 2007-09-16 | Bayer Pharmaceuticals Corporation | Inhibidor de rho-cinasa. |
ES2305435T3 (es) * | 2002-01-10 | 2008-11-01 | Bayer Healthcare Ag | Inhibidores de la rho-quinasa. |
GB0206215D0 (en) * | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
GB0305929D0 (en) * | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
GB0319227D0 (en) * | 2003-08-15 | 2003-09-17 | Novartis Ag | Organic compounds |
CN1798734A (zh) * | 2003-04-04 | 2006-07-05 | Irm责任有限公司 | 作为蛋白激酶抑制剂的新化合物和组合物 |
US20050014753A1 (en) * | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
WO2005016528A2 (en) * | 2003-08-15 | 2005-02-24 | Irm Llc | 6-substituted anilino purines as rtk inhibitors |
PL1660458T3 (pl) * | 2003-08-15 | 2012-07-31 | Novartis Ag | 2,4-pirymidynodwuaminy stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego |
GB0407723D0 (en) * | 2004-04-05 | 2004-05-12 | Novartis Ag | Organic compounds |
EP1598343A1 (de) * | 2004-05-19 | 2005-11-23 | Boehringer Ingelheim International GmbH | 2-Arylaminopyrimidine als PLK Inhibitoren |
GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
WO2006074057A2 (en) * | 2004-12-30 | 2006-07-13 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
EP2684874B1 (en) * | 2006-10-23 | 2017-05-17 | Cephalon, Inc. | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors |
CA2671744C (en) * | 2006-12-08 | 2012-08-28 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
-
2007
- 2007-11-20 CA CA2671744A patent/CA2671744C/en active Active
- 2007-11-20 DK DK07864693.2T patent/DK2091918T3/en active
- 2007-11-20 BR BRPI0720264-4A patent/BRPI0720264B1/pt active IP Right Grant
- 2007-11-20 CN CN201310574409.XA patent/CN103641833A/zh active Pending
- 2007-11-20 ME MEP-2009-216A patent/ME00811B/me unknown
- 2007-11-20 AU AU2007333394A patent/AU2007333394C1/en active Active
- 2007-11-20 PL PL07864693T patent/PL2091918T3/pl unknown
- 2007-11-20 KR KR1020097014175A patent/KR101149295B1/ko active Protection Beyond IP Right Term
- 2007-11-20 PT PT78646932T patent/PT2091918E/pt unknown
- 2007-11-20 CN CN201310573341.3A patent/CN103641816A/zh active Pending
- 2007-11-20 EA EA200970557A patent/EA017405B9/ru not_active IP Right Cessation
- 2007-11-20 JP JP2009540379A patent/JP5208123B2/ja active Active
- 2007-11-20 WO PCT/US2007/085304 patent/WO2008073687A2/en active Application Filing
- 2007-11-20 EP EP07864693.2A patent/EP2091918B1/en active Active
- 2007-11-20 MX MX2009006081A patent/MX2009006081A/es active IP Right Grant
-
2009
- 2009-05-25 IL IL198936A patent/IL198936A0/en active Protection Beyond IP Right Term
- 2009-05-25 ZA ZA2009/03601A patent/ZA200903601B/en unknown
- 2009-05-27 MA MA31924A patent/MA30923B1/fr unknown
- 2009-05-28 CR CR10832A patent/CR10832A/es unknown
- 2009-06-03 GT GT200900147A patent/GT200900147A/es unknown
- 2009-06-03 TN TNP2009000225A patent/TN2009000225A1/fr unknown
- 2009-06-08 SV SV2009003290A patent/SV2009003290A/es unknown
- 2009-06-30 NO NO20092472A patent/NO338069B1/no active Protection Beyond IP Right Term
- 2009-07-02 SM SM200900058T patent/SMP200900058B/it unknown
- 2009-07-08 EC EC2009009500A patent/ECSP099500A/es unknown
- 2009-07-08 CO CO09070739A patent/CO6231028A2/es active IP Right Grant
-
2010
- 2010-08-09 AU AU2010210018A patent/AU2010210018B2/en not_active Ceased
- 2010-08-09 AU AU2010210019A patent/AU2010210019C1/en not_active Ceased
-
2012
- 2012-07-06 JP JP2012152703A patent/JP5513558B2/ja active Active
-
2013
- 2013-02-19 JP JP2013030284A patent/JP2013144683A/ja active Pending
-
2015
- 2015-08-26 FR FR15C0058C patent/FR15C0058I2/fr active Active
- 2015-09-29 LT LTPA2015034C patent/LTC2091918I2/lt unknown
- 2015-10-02 HU HUS1500049C patent/HUS1500049I1/hu unknown
- 2015-10-07 NL NL300763C patent/NL300763I1/nl unknown
- 2015-11-02 CY CY2015043C patent/CY2015043I1/el unknown
-
2016
- 2016-02-29 NO NO20160333A patent/NO20160333A1/no not_active Application Discontinuation
- 2016-08-10 NO NO2016014C patent/NO2016014I2/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6231028A2 (es) | Compuestos y composiciones como inhibidores de la proteina quinasa | |
AR077849A2 (es) | Compuestos y composiciones como inhibidores de proteina quinasa | |
JP2017528524A5 (es) | ||
AR055592A1 (es) | Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace) | |
AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
AR054799A1 (es) | Derivados de oxindol | |
TW200833686A (en) | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | |
AR088226A1 (es) | Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas | |
NO20070336L (no) | Indolderivater som histamin-reseptorantagonister | |
AR053301A1 (es) | Derivados de pirazina y su uso farmaceutico | |
AR072166A1 (es) | Derivado de piperidina y su uso como inhibidor de renina superior | |
AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
CO5580824A2 (es) | Derivados de fenil o heteroaril amino alcano como antagonis- tas del receptor ip | |
MX2011011875A (es) | Compuesto de carboxamida heterociclica diamino. | |
DOP2010000226A (es) | Compuestos triciclicos que tienen actividad antagonista de factor de liberacion de corticotropina y composiciones farmaceuticas que contienen los mismos | |
AR066583A1 (es) | Derivados de 3,3-espiroindolinona | |
ATE496043T1 (de) | 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren | |
AR074435A1 (es) | Derivados de 1,3-benzotiazol, medicamentos que los contienen y uso de los mismos en el tratamiento del cancer. | |
MX2010000658A (es) | Derivados de pirimidina 934. | |
CO6260074A2 (es) | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
CR11483A (es) | Inhibidores de peptido desformilasa | |
CY1114927T1 (el) | Νεα 2-υποκατεστημενα παραγωγα μεθυλο πεναμης | |
AR079497A1 (es) | Derivados fenilimidazol que comprenden un enlazante de etinileno como inhibidores de enzima pde10a | |
BR112019021853A2 (pt) | Compostos de inibidor de vmat2 e composições dos mesmos | |
PE20090216A1 (es) | Compuestos triazolil aminopirimidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted |